Alnylam

ALN-VSP Data at 2011 ASCO Meeting

At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement.





Data presented showed that ALN-VSP was generally well tolerated and showed evidence for anti-tumor activity.  Importantly, ALN-VSP was found to mediate RNAi activity in both hepatic and extra-hepatic tumors.  We are very encouraged by these results, as they represent an important milestone in the advancement of RNAi therapeutics – showing for the first time both clinical activity and  proof of the RNAi mechanism in man with an RNAi therapeutic.